Home / Health / CorTec BCI Breakthrough for Stroke Recovery
CorTec BCI Breakthrough for Stroke Recovery
9 Apr
Summary
- CorTec's BCI achieved FDA breakthrough status for stroke rehabilitation.
- The device helps motor recovery via direct cortical stimulation.
- Two patients were implanted, with more indications planned.
CorTec has achieved a major breakthrough as its Brain Interchange system earned FDA designation for stroke rehabilitation. This innovative brain-computer interface (BCI) is designed to support motor recovery in individuals with chronic stroke-related impairments by providing direct cortical electrical stimulation, guided by recorded brain signals.
The company's CEO expressed excitement, highlighting the system's potential to address a significant unmet need. Data from a 500-day study demonstrated signal stability, providing strong momentum for CorTec's advancement. The system is currently undergoing an investigational device exemption (IDE) study at the University of Washington, with two patients successfully implanted since May 2024.
Beyond stroke rehabilitation, CorTec's BCI is being explored for epilepsy, paralysis, and depression. The global neurology devices market is anticipated to surpass $25 billion by 2034, with BCIs like CorTec's poised for commercialization around 2030. This FDA designation is expected to accelerate clinical trial planning and future regulatory milestones.
